An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats

Authors

Sarah Cook
Luke Wittenburg
Victoria C Yan
Jacob H Theil
Diego Castillo
Krystle L Reagan
Sonyia Williams
Cong-Dat Pham
Chun Li
Florian L Muller
Brian G Murphy

Publication Date

11-1-2022

Journal

Viruses

Abstract

Feline infectious peritonitis (FIP) is a fatal disease of cats that currently lacks licensed and affordable vaccines or antiviral therapeutics. The disease has a spectrum of clinical presentations including an effusive ("wet") form and non-effusive ("dry") form, both of which may be complicated by neurologic or ocular involvement. The feline coronavirus (FCoV) biotype, termed feline infectious peritonitis virus (FIPV), is the etiologic agent of FIP. The objective of this study was to determine and compare the in vitro antiviral efficacies of the viral protease inhibitors GC376 and nirmatrelvir and the nucleoside analogs remdesivir (RDV), GS-441524, molnupiravir (MPV; EIDD-2801), and β-D-N

Keywords

Cats, Animals, Coronavirus, Feline, Feline Infectious Peritonitis, Antiviral Agents, Biological Assay

Comments

This article has been corrected. See Viruses. 2024 March 04; 16(3): 397.

DOI

10.3390/v14112429

PMID

36366527

PMCID

PMC9697187

PubMedCentral® Posted Date

November 2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes